Get notified when LFST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (worsened) — Material weaknesses in internal control over financial reporting, first identified in 2019, remain unremediated as of June 30, 2026, with remediation actions narrowed to access management controls.
LifeStance swings to profit, revenue up 26.1% to $435.4M, launches up to $100M buyback
Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read
Key Changes
-
high
Revenue rose 26.1% to $435.4M in Q2 2026, driven by 834 more clinicians and 19% more patient visits.
MD&A: Revenue verify on EDGAR → -
high
Operating income swung from a $2.95M loss to $30.65M in Q2; six-month operating income reached $52.94M vs a $1.35M loss a year ago.
MD&A: Operating income verify on EDGAR → -
high
Net income was $23.6M for the quarter, compared to a loss in the prior year.
Key Financials view on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (AAL 10-Q) is open in full — no account needed.
Partner
Trade LFST commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 27, 2026 · How we verify